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Abstract
Background: The TNF/LTA locus has been a long-standing T2D candidate gene. Several studies have examined 
association of TNF/LTA SNPs with T2D but the majority have been small-scale and produced no convincing evidence of 
association. The purpose of this study is to examine T2D association of tag SNPs in the TNF/LTA region capturing the 
majority of common variation in a large-scale sample set of UK/Irish origin.
Methods: This study comprised a case-control (1520 cases and 2570 control samples) and a family-based component 
(423 parent-offspring trios). Eleven tag SNPs (rs928815, rs909253, rs746868, rs1041981 (T60N), rs1800750, rs1800629 (G-
308A), rs361525 (G-238A), rs3093662, rs3093664, rs3093665, and rs3093668) were selected across the TNF/LTA locus and 
genotyped using a fluorescence-based competitive allele specific assay. Quality control of the obtained genotypes was 
performed prior to single- and multi-point association analyses under the additive model.
Results: We did not find any consistent SNP associations with T2D in the case-control or family-based datasets.
Conclusions: The present study, designed to analyse a set of tag SNPs specifically selected to capture the majority of 
common variation in the TNF/LTA gene region, found no robust evidence for association with T2D. To investigate the 
presence of smaller effects of TNF/LTA gene variation with T2D, a large-scale meta-analysis will be required.
Background
Type 2 diabetes (T2D) is a complex disease influenced by
environmental and genetic factors. Genetic association
studies have thus far identified at least 20 replicating T2D
susceptibility loci of modest to small effect, which
together explain less than 10% of the genetic component
of disease [1,2]. Several genome-wide association scans
(GWAS) have been carried out for T2D [3-10]. These
have used a variety of genotyping platforms with different
SNP content, typically capturing over 80% of common
variation in European-descent populations. Although this
extent of coverage, in combination with imputation
approaches [11], reduces the need for candidate gene
studies, in-depth investigation of variation at loci of inter-
est can conceivably prove useful in characterising them
further.
The TNF/LTA locus has been a long-standing T2D can-
didate gene. T2D and obesity have been hypothesised to
have an inflammatory basis [12,13]. Insulin resistance is
associated with increased plasma levels of proinflamma-
tory cytokines such as TNF and IL6, and with interac-
tions between TNF and NFkappaB that lead to an
increase of oxidative stress [14-16].
The genes coding for TNF and LTA reside in the class
III MHC region on chromosome 6p21.3. TNF and LTA
are members of the TNF ligand superfamily, bind the
same TNF receptors and mediate similar pleiotropic
effects [17,18]. Of the multiple SNPs in the TNF/LTA
gene region, the rs361525 (G-238A) and rs1800629 (G-
308A) TNF promoter variants, and the rs1041981 (T60N)
LTA  variant have been the most frequently studied in
T2D. The majority of studies of TNF/LTA  SNPs have
been small-scale, with some notable exceptions [17], and
have produced no convincing evidence for association
with the disease [19-27].
The Wellcome Trust Case Control Consortium
(WTCCC) T2D GWAS examined 17 directly typed and
imputed SNPs from the TNF/LTA  gene region and
detected no association with T2D in 2000 cases and 3000
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controls from the UK [6,28]. In addition, a GWAS meta-
analysis for T2D carried out by the DIAGRAM consor-
tium, which examined the same 17 directly genotyped
and imputed SNPs in the TNF/LTA region in samples
from three sources (Diabetes Genetics Initiative (DGI),
Finland-United States Investigation of NIDDM Genetics
(FUSION) and WTCCC) also found no association
between  TNF/LTA  SNPs and T2D [28]. However, the
WTCCC genotyping platform (Affymetrix 500k) and
HapMap-based imputation do not provide exhaustive
coverage of common variation in this gene region. To
increase coverage, we carried out a genetic association
study of the TNF/LTA loci in a total of 5359 samples from
the UK by typing additional SNPs, selected on the basis of
sequence data to better capture variation in the region.
Methods
Subjects
This study comprised a case-control and a family-based
component. The case-control dataset included 1520
cases from the Diabetes UK Warren 2 Sib Pair Repository
(61.5% males) and 2570 control samples from the 1958
British birth cohort (n = 2027, 50.6% males) [29], and the
HRC control collection (n = 543, 49.9% males) derived
from UK blood donors and available from the European
Centre for Cell Culture (ECACC, CAMR, Salisbury, UK).
The family-based dataset comprised 423 parent-offspring
trios (58.5% male probands) from the Diabetes UK War-
ren 2 Trios (W2T) Repository. W2T probands were
selected by strict clinical, immunological and genetic cri-
teria as previously described [30]. All cases included in
the present study had T2D diagnosed according to the
World Health Organization criteria and were selected for
early diabetes onset and/or positive family history.
Importantly, autoimmune diabetes was excluded based
on GAD antibody typing, age of disease onset above 25,
insulin independence following diagnosis, no ketoacedo-
sis and no first degree relatives with type 1 diabetes
[30,31]. Clinical characteristics of the cases are provided
in Table 1. 58.2% of WTCCC cases and 35.3% of WTCCC
controls overlapped with the samples examined as part of
our study. All subjects were exclusively of UK/Irish origin
and provided signed informed consent prior to blood
sampling. Reported investigations have been carried out
following the principles of the Declaration of Helsinki as
revised in 2000. Ethical oversight for collection and use of
the T2D cases was provided from MREC 00/6/55, Peter-
borough and Fenland LREC 05/Q0106/78 and from over
100 individual local research ethics committee approvals.
Use of the 1958 Birth Cohort samples is in accordance
with Joint UCL/UCLH Research Ethics Committee A
approval 08/H0714/40 and South-East Multi-Centre
Research Ethics Committee approval MREC 01/1/44.
The HRC samples are a commercially available set of ano-
nymised DNA samples from blood donors sourced from
the Health Protection Agency Culture Collection and
approved for research use only.
SNP Selection and Genotyping
Eleven haplotype-tagging SNPs (tag SNPs) (rs928815,
rs909253, rs746868, rs1041981 (T60N), rs1800750,
rs1800629 (G-308A), rs361525 (G-238A), rs3093662,
rs3093664, rs3093665, rs3093668) were selected across
the  TNF  and  LTA  loci from sequencing and genotype
data generated in 32 Caucasian trios as previously
described [32,33] (Table 2). Genotypes for this study were
determined using a fluorescence-based competitive allele
specific assay (Kaspar, Kbioscience, UK). Genotyping and
SNP selection details are available from the authors on
request. When we investigated linkage disequilibrium
(LD) between the SNPs, we found SNPs rs928815 and
rs746868, and SNPs rs909253 and rs1041981 to be in
tight LD with each other (r2 > 0.8). SNP pairs rs361525-
rs3093662, rs361525-rs3093668 and rs3093662-
rs3093664 displayed moderate LD (0.6 < r2 < 0.8), while
all other investigated SNPs showed no or very weak pair-
wise LD (0 < r2 < 0.52) (Additional file 1, Figures S1a and
S1b). Eight of the 11 studied tag SNPs have been geno-
typed in the HapMap (rs928815, rs909253, rs1041981,
rs1800750, rs1800629, rs3093662, rs3093665, rs3093668).
These 8 variants capture 61.1% of common (MAF > 0.05)
variation across the TNF/LTA  gene region (overall 18
SNPs in the HapMap database) at an r2 threshold of ≥0.8,
based on the HapMap (CEU population, Rel 24/PhaseII
Nov 08 [34]). The proportion of common variation across
the region captured by the typed tag SNPs was calculated
Table 1: Clinical characteristics of T2D cases
Cohort Female Male Average Age At Study (years) Average AODc (years) Average BMI (kg/m2)
W2Ca 583 932 60.23 51.46 31.80
W2Tb 173 249 46.26 40.44 32.91
aW2C - Warren 2 Cohort; bW2T - Warren 2 Trios probands; cAOD - Age of diagnosisBoraska et al. BMC Medical Genetics 2010, 11:69
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on a multimarker tagging basis using Tagger [35]. How-
ever, this is an underestimate of the capture of common
variation, since the 3 remaining non-HapMap variants
were excluded from this calculation. T o asses coverage
further we performed another calculation on the basis of
the 1000 genomes project data (http://www.1000
genomes.org) April 2009 release).
Statistical analysis
Quality control (QC) of the obtained genotypes was per-
formed prior to association analysis. The SNP genotyping
success rates ranged from 93.3% to 98.6%. We evaluated
the comparative rate of missing genotypes between cases
and controls using Plink (version 1.00) [36] and excluded
rs3093662 from the case-control association analysis due
to low call rate. The tag SNPs were tested for deviation
from Hardy-Weinberg equilibrium (HWE) in affected
and healthy individuals separately using Stata v. 8 (Stata
Corporation, College Station, TX, USA) and Plink (ver-
sion 1.00) [36]. No deviations from HWE were observed.
Minor allele frequencies (MAFs) of controls in both stud-
ies were compared with the National Center for Biotech-
nology Information SNP database (NCBI dbSNP) MAFs
for the CEU population and showed no significant differ-
ences. Testing of Mendelian inheritance using Plink and
Haploview [36,37] identified inconsistencies in one fam-
ily, which was excluded from further analysis. After QC,
10 tag SNPs were taken forward to case-control associa-
tion analyses and 11 tag SNPs were included in family-
based association analysis.
Single-point case-control association analyses were
carried out using Stata v. 8 (Stata Corporation, College
Station, TX, USA). Multi-point case-control association
analyses of fixed haplotype sizes (sliding windows of 2-10
SNPs shifting 1 SNP at a time) were performed using the
expectation-maximisation algorithm-based approach
implemented in Plink [36]. Single-point and multi-point
(sliding windows of 2-11 SNPs) family-based association
analyses were carried out using implementations of the
transmission disequilibrium test (TDT) in Plink [36].
10,000 permutations were run for each association analy-
sis. r2 and D' measures of pairwise LD were calculated for
all SNPs using Haploview [37]. Power was calculated
under the log-additive model for a range of effect-sizes
(1.1<OR>2) at α = 0.05 using Quanto [38]. All association
analyses are unadjusted (e.g. for BMI, blood pressure and
other environmental variables), as these data were not
available to us. We did not investigate gene-environment
interactions.
Table 2: Characteristics of 11 TNF/LTA tag SNPs.
dbSNP rs number Position on chr. 6a Alternative name Gene location Alleles (C:M)b dbSNP CEU MAFc
rs928815 31639194 / 5' LTA G:T 0.383
rs909253 31648292 252G > A LTA-intron 1 T:C 0.358
rs746868 31648408 / LTA-intron 1 G:C 0.405
rs1041981 31648763 Thr26Asn;T60N; 804C > A LTA-exon 3 C:A 0.358
rs1800750 31650942 -376 G > A 5' of TNF G:A 0.008
rs1800629 31651010 -308 G > A 5' of TNF A:G 0.217
rs361525 31651080 -238 G > A 5' of TNF G:A 0.068
rs3093662 31652168 IVS1-122A > G; +851 TNF-intron 1 A:G 0.071
rs3093664 31652621 / TNF-intron 3 A:G 0.065
rs3093665 31653370 / TNF - 3'UTR A:C 0.017
rs3093668 31654474 / 3' of TNF G:C 0.042
aBased on UCSC Genome Browser; bC:M - common allele: minor allele; cMAF - minor allele frequency for the CEU population based on NCBI 
dbSNP databaseBoraska et al. BMC Medical Genetics 2010, 11:69
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Results
Genotype distributions for the 11 TNF/LTA tag SNPs in
the case-control and parent-offspring datasets are shown
in Additional file 1, Table S1 and Table S2, respectively.
Overall, we did not identify any consistent significant
SNP associations with disease. The most frequently stud-
ied SNPs, rs1800629 (G-308A), rs361525 (G-238A), and
rs1041981 (T60N) did not show robust association with
the disease in any dataset (Table 3). Exhaustive multi-
marker case-control analyses did not identify any strong
haplotypic associations (data not shown). There were no
statistically significant deviations in the transmission of
alleles from parents to affected probands by single-point
(Table 4) or haplotype-based analysis (data not shown).
Our study had 80% power at α = 0.05 to identify modest/
large effect sizes (OR > 1.3) at common loci (Additional
file 1, Tables S3a and S3b).
In the WTCCC GWAS [5,28], a total number of 17 (one
directly genotyped, rs1799964, and 16 imputed) SNPs
from the TNF/LTA  gene region were investigated and
showed no association with T2D. The case-control asso-
ciation results of the most frequently studied SNPs,
rs1800629 (G-308A), rs361525 (G-238A) and rs1041981
(T60N) from the present study and from the WTCCC
dataset (across which there is considerable overlap) is
shown in Table 5. Five of the tag SNPs from the present
study (rs746868, rs1800750, rs361525, rs3093664 and
rs3093665) were not directly typed or imputed in the
WTCCC GWAS. To assess the extent of additional cover-
age these 5 SNPs offer , we examined LD based on our
genotype data in T2D cases and controls. SNPs rs746868
and rs361525 are in high LD (r2 = 0.99 and r2 = 0.79) with
two of the WTCCC-typed SNPs, rs928815 and rs3093668
respectively. The remaining 3 SNPs that have not been
examined in the WTCCC (rs1800750, rs3093664 and
rs3093665) demonstrate low LD with WTCCC-typed and
other HapMap SNPs (0 < r2 < 0.52) (Additional file 1, Fig-
ures S1a and S1b). Therefore these polymorphisms cap-
ture additional variation missed by the WTCCC study.
We investigated capture further on the basis of the 1000
genomes project data. Four of our 11 tag SNPs (rs909253,
rs1800750, rs3093662 and rs3093665) were not found in
the 1000G dataset and the remaining 7 tag SNPs capture
60.6% of common variation (overall 33 TNF/LTA SNPs in
the 1000G dataset) on a multimarker tagging basis at an
r2 threshold of ≥0.8. This is again an underestimate of the
TNF/LTA common variation capture by our tag SNPs.
Discussion
In this study of 11 tag SNPs, we find no consistent evi-
dence for association between TNF/LTA region variation
and T2D. The present study was designed to analyse a set
of tag SNPs specifically selected to capture the majority of
common variation in the TNF/LTA gene region based on
proprietary sequence and genotype data [32,33].
Although a proportion of the investigated variants had
been examined as part of the WTCCC GWAS [5,28], this
study provides further capture of common variation
across the region. However, the overall conclusion
remains unchanged - there was no evidence of associa-
tion with disease.
This is one of the largest studies to date, showing no
association between TNF/LTA  variation and T2D. A
recent meta-analysis (2106 cases and 2920 controls) of
the rs361525 (G-238A) variant did not detect a significant
association with T2D [23]. Similar meta-analyses of all
reported association studies for the rs1800629 (G-308A)
and rs1041981 (T60N) SNPs, which have been widely
investigated with respect to T2D, may boost power to
detect possible small effects at these loci.
T2D is a complex disease caused by complex interplay
between environmental and genetic factors. A limitation
of our study is that we have not been able to adjust for or
investigate interaction of SNPs with BMI, age, gender,
blood pressure, serum lipid levels etc. as these data were
unavailable to us. In addition, even though our study
examined the majority of common variation across the
region, it is possible that causal, associated variants may
have been missed.
Table 3: Case-control association analysis results for the 10 
TNF/LTA tag SNPs
SNP OR allele ORa 95% CIa p value
rs928815 T 1.056 0.96-1.16 0.255
rs909253 T 0.889 0.81-0.98 0.015
rs746868 C 1.066 0.97-1.17 0.18
rs1041981 (T60N) C 0.892 0.81-0.98 0.019
rs1800750 A 1.001 0.64-1.54 0.996
rs1800629 (G-308A) A 0.984 0.88-1.11 0.791
rs361525 (G-238A) G 0.981 0.81-1.19 0.845
rs3093664 A 0.996 0.85-1.17 0.958
rs3093665 C 1.192 0.86-1.64 0.268
rs3093668 C 1.053 0.85-1.3 0.625
aallelic OR and 95% confidence intervals.Boraska et al. BMC Medical Genetics 2010, 11:69
http://www.biomedcentral.com/1471-2350/11/69
Page 5 of 7
Conclusions
The purpose of this study was to examine if genetic varia-
tion in the genes encoding inflammatory proteins TNF
and LTA alter the risk of developing T2D. We tested a
carefully selected set of haplotype tagging SNPs that cap-
ture the majority of common variation in the TNF/LTA
gene region in case-control and parent-offspring samples
and find no robust evidence for association. Large-scale
meta-analyses will be required to investigate the presence
of smaller effects at polymorphic sites in the TNF/LTA
gene region.
Table 4: Transmission disequilibrium analysis of 11 TNF/LTA tag SNPs in T2D parent-offspring trios
SNP Na A1:A2b MAFc T:Ud ORe
95% CI f p value
rs928815 322 T:G 0.359 132:165 0.8 0.64-1.01 0.055
rs909253 321 C:T 0.358 157:145 1.083 0.86-1.36 0.489
rs746868 324 C:G 0.362 135:163 0.828 0.66-1.04 0.104
rs1041981 (T60N) 301 A:C 0.355 146:138 1.058 0.84-1.34 0.635
rs1800750 327 A:G 0.012 7:12 0.583 0.23-1.48 0.251
rs1800629 (G-308A) 237 G:A 0.195 73:70 1.043 0.75-1.45 0.801
rs361525 (G-238A) 324 A:G 0.055 35:35 1 0.63-1.59 1
rs3093662 321 G:A 0.079 47:44 1.068 0.71-1.61 0.753
rs3093664 321 G:A 0.086 55:43 1.279 0.86-1.91 0.225
rs3093665 324 C:A 0.023 14:12 1.167 0.54-2.52 0.694
rs3093668 321 C:G 0.045 31:22 1.409 0.82-2.43 0.216
aN - number of informative trios; bA1:A2 - minor allele vs. major allele; cMAF - minor allele frequency in affected probands; dcopies of the minor 
allele transmitted (T) and untransmitted (U), eodds ratios (OR), f95% lower and upper confidence intervals.
Table 5: The comparison of association results for T60N, G-308A and G-238A between the present study and the WTCCC 
T2D GWAS
SNP OR allele ORa 95% CIa p-value WTCCC SNPb ORa 95% CIa p-value
rs1041981 (T60N) C 0.89 0.81-0.98 0.02 rs1041981 1.06 0.96-1.16 0.67
rs1800629 (G-308A) A 0.98 0.88-1.11 0.79 rs1800629 1.05 0.93-1.19 0.56
rs361525 (G-238A) G 0.98 0.81-1.19 0.85 rs3093668 (proxy for rs361525) 0.86 0.71-1.05 0.21
aOR - allelic odds ratio and 95% confidence intervals; bAll three SNPs were imputed in the WTCCC data set. 58.2% of WTCCC cases and 35.3% of 
WTCCC controls overlapped with the samples from our study.Boraska et al. BMC Medical Genetics 2010, 11:69
http://www.biomedcentral.com/1471-2350/11/69
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